Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.
Novartis updates US label on Gilenya® following discussions with the FDA
Proton Density MRI Increases Detection of Cervical Spinal Cord Multiple Sclerosis Lesions Compared with T2-Weighted Fast Spin-Echo.
IL-1β induces hypomyelination in the periventricular white matter through inhibition of oligodendrocyte progenitor cell maturation via FYN/MEK/ERK signaling pathway in septic neonatal rats.
Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening.
New data at AAN to confirm efficacy of Novartis' Gilenya® across four key measures of MS disease activity, including brain volume loss
Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis-Report of Two Cases.
Mesenchymal stem cells as treatment for MS - progress to date.
Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis?
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS] (RECYCLINE)
Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis (PROMESS)
Sex ratio of multiple sclerosis in Canada: a longitudinal study.
New Drug Review 2010: Ustekinumab (Stelara, Centocor Ortho Biotech)
Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells.
Immunopathology of multiple sclerosis.
Correlation between demyelinating lesions and executive function decline in a sample of Mexican patients with multiple sclerosis.
Tractography Analysis of 5 White Matter Bundles and Their Clinical and Cognitive Correlates in Early-Course Schizophrenia.
Magnetic Resonance Spectroscopy Markers of Disease Progression in Multiple Sclerosis.
Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis.
Painful Tonic Spasm in Neuromyelitis Optica: Incidence, Diagnostic Utility, and Clinical Characteristics.
Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis.
Month of Birth Does Not Seem to Interfere with the Development of Multiple Sclerosis Later in Life in Brazilian Patients.
Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, th17- and activated B-cells and correlates with progression.
Association of NOD1 and NOD2 polymorphisms with Guillain-Barré syndrome in Northern Indian population.
Functional role of TRP channels in modulating ER stress and Autophagy.
Pages
« first
‹ previous
…
168
169
170
171
172
173
174
175
176
…
next ›
last »